The state of Texas currently has 53 active clinical trials seeking participants for COVID19 research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
COPD Circuit Exercise
NCT05395390
Recruiting
This study is being done to understand body's response to hybrid home-based and on-site rehabilitation program utilizing individually tailored exercises throughout a total of 18 sessions with 12 of them occurring onsite, in people with and without chronic respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and Obstructive Sleep Apnea (OSA) and in individuals recovered from COVID-19. Exercise training programs vary widely for people with COPD, OSA, and during prolonged reco... Read More
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/24/2022
Locations: Texas A&M University, College Station, Texas
Conditions: OSA, Covid19, Residual Symptoms of COVID 19, COPD
Register for Updates
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress
NCT04905836
Recruiting
This is a Phase 2 study to assess COVI-MSC in the setting of current standard of care in hospitalized subjects with RT-PCR confirmed SARS-CoV-2 (COVID-19) infection and acute respiratory distress / acute respiratory distress syndrome.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/07/2022
Locations: PRX Research/Dallas Regional Medical Center, Mesquite, Texas
Conditions: Covid19
Register for Updates
Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting
NCT04840459
Recruiting
No therapeutic agent is currently approved for the treatment of SARSCoV-2 infection. More importantly, no intervention is currently available to mitigate the progression of disease from mid/moderate to serve particularly in high risk patients. Recognizing this limitation and urgency of finding a treatment for COVID-19, the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergencyuse of the unapproved product bamlanivimab or casirivimab + imde... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
03/14/2022
Locations: DHR Health Institute for Research and Development, Edinburg, Texas +2 locations
Conditions: Covid19
Register for Updates
PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
NCT05279365
Recruiting
The recent rise in infections with the Omicron variant of the SARS-CoV-2 is alarming. Equally disconcerting is the fact that individuals who were previously vaccinated (< 6 months) and have co-morbidities that are considered high risk, are getting re-infected...a process referred to as "breakthrough". There is some evidence that in these high risk individuals, the gradual decrease in immunity against the virus as depicted by a drop in anti-SARS-CoV-2 antibodies, is responsible (partially or whol... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2022
Locations: Brownsville Independent School District, Brownsville, Texas +3 locations
Conditions: SARS CoV 2 Infection, COVID-19
Register for Updates
Natural History of COVID-19-Related Atrial Fibrillation
NCT04830774
Recruiting
The unCOVer-AF prospective, multicenter registry aims at determining the natural history of atrial fibrillation (AF) via continuous cardiac rhythm monitoring in patients with a first arrhythmic episode during COVID-19 hospitalization.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2021
Locations: Texas Cardiac Arrhythmia Institute, Austin, Texas
Conditions: COVID-19, Atrial Fibrillation New Onset
Register for Updates